Advanced search
Publication Cover
Emerging Microbes & Infections Volume 3, 2014 - Issue 1
Submit an article Journal homepage
3,238
Views
106
CrossRef citations to date
0
Altmetric
Reviews

The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections

Adrian EgliInfection Biology, Department of Biomedicine, University Hospital of Basel, 4031 Basel, Switzerland;Clinical Microbiology, University Hospital of Basel, 4031 Basel, SwitzerlandCorrespondence[email protected]
,
Deanna M SanterDepartment of Medical Microbiology and Immunology, and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
,
Daire O’SheaDepartment of Medical Microbiology and Immunology, and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada;Division of Infectious Diseases, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
,
D Lorne TyrrellDepartment of Medical Microbiology and Immunology, and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
&
Michael HoughtonDepartment of Medical Microbiology and Immunology, and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
Pages 1-12 | Received 23 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • Isaacs A, Lindenmann J.Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci1957;147: 258–267.
  • Kotenko SV, Langer JA.Full house: 12 receptors for 27 cytokines. Int Immunopharmacol2004;4: 593–608.
  • Allen G, Fantes KH.A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature1980;287: 408–411.
  • Seto MH, Harkins RN, Adler M, Whitlow M, Church WB, Croze E.Homology model of human interferon-alpha 8 and its receptor complex. Protein Sci1995;4: 655–670.
  • Streuli M, Nagata S, Weissmann C.At least three human type alpha interferons: structure of alpha 2. Science1980;209: 1343–1347.
  • Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S.The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci USA1997;94: 11813–11818.
  • Senda T, Shimazu T, Matsuda S et al.Three-dimensional crystal structure of recombinant murine interferon-beta. EMBO J1992;11: 3193–3201.
  • Ealick SE, Cook WJ, Vijay-Kumar S et al.Three-dimensional structure of recombinant human interferon-gamma. Science1991;252: 698–702.
  • Kotenko SV, Gallagher G, Baurin VV et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol2003;4: 69–77.
  • Sheppard P, Kindsvogel W, Xu W et al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol2003;4: 63–68.
  • Gad HH, Hamming OJ, Hartmann R.The structure of human interferon lambda and what it has taught us. J Interferon Cytokine Res2010;30: 565–571.
  • Kumaran J, Wei L, Kotra LP, Fish EN.A structural basis for interferon-alpha–receptor interactions. FASEB J2007;21: 3288–3296.
  • Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, Heim MH.Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem1998;254: 514–519.
  • Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I.Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood1999;93: 1980–1991.
  • Sadler AJ, Williams BR.Interferon-inducible antiviral effectors. Nat Rev Immunol2008;8: 559–568.
  • Aaronson DS, Horvath CM.A road map for those who don’t know JAK–STAT. Science2002;296: 1653–1655.
  • Gonzalez-Navajas JM, Lee J, David M, Raz E.Immunomodulatory functions of type I interferons. Nat Rev Immunol2012;12: 125–135.
  • Platanias LC.Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol2005;5: 375–386.
  • Blouin CM, Lamaze C.Interferon gamma receptor: the beginning of the journey. Front Immunol2013;4: 267.
  • Hamming OJ, Terczynska-Dyla E, Vieyres G et al.Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J2013;32: 3055–3065.
  • Prokunina-Olsson L, Muchmore B, Tang W et al.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet2013;45: 164–171.
  • Kotenko SV.The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev2002;13: 223–240.
  • Donnelly RP, Kotenko SV.Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res2010;30: 555–564.
  • Fox BA, Sheppard PO, O’Hara PJ.The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS ONE2009;4: e4933.
  • Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A.Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J Mol Biol2010;404: 650–664.
  • Rauch A, Kutalik Z, Descombes P et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology2010;138: 1338–1345.
  • Hillyer P, Mane VP, Schramm LM et al.Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol2012;90: 774–783.
  • Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R.Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun2009;10: 125–131.
  • Bolen CR, Ding S, Robek MD, Kleinstein SH.Dynamic expression profiling of Type I and Type III Interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology2014;59: 1262–1272.
  • Spann KM, Tran KC, Chi B, Rabin RL, Collins PL.Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol2004;78: 4363–4369.
  • Ioannidis I, Ye F, McNally B, Willette M, Flano E.Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol2013;87: 3261–3270.
  • Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR.Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80: 4501–4509.
  • Coccia EM, Severa M, Giacomini E et al.Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol2004;34: 796–805.
  • Langhans B, Kupfer B, Braunschweiger I et al.Interferon-lambda serum levels in hepatitis C. J Hepatol2011;54: 859–865.
  • Diegelmann J, Beigel F, Zitzmann K et al.Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE2010;5: e15200.
  • Mihm S, Frese M, Meier V et al.Interferon type I gene expression in chronic hepatitis C. Lab Invest2004;84: 1148–1159.
  • Bowie AG, Unterholzner L.Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol2008;8: 911–922.
  • Stoltz M, Klingstrom J.Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. J Virology2010;84: 9140–9148.
  • Ank N, Iversen MB, Bartholdy C et al.An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol2008;180: 2474–2485.
  • Hou W, Wang X, Ye L et al.Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol2009;83: 3834–3842.
  • Chandra PK, Bao L, Song K et al.HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol2014;184: 214–229.
  • Sheahan T, Morrison TE, Funkhouser W et al.MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog2008;4: e1000240.
  • Khaitov MR, Laza-Stanca V, Edwards MR et al.Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy2009;64: 375–386.
  • Jewell NA, Cline T, Mertz SE et al.Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol2010;84: 11515–11522.
  • Wolk K, Witte K, Witte E et al.Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol2008;83: 1181–1193.
  • Yin Z, Dai J, Deng J et al.Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol2012;189: 2735–2745.
  • Lauterbach H, Bathke B, Gilles S et al.Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med2010;207: 2703–2717.
  • Megjugorac NJ, Gallagher GE, Gallagher G.IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood2010;115: 4185–4190.
  • Egli A, Levin A, Santer DM et al.Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus. J Infect Dis;e-pub ahead of print 8 April 2014. doi: https://doi.org/10.1093/infdis/jiu144.
  • McFadden G, Mohamed MR, Rahman MM, Bartee E.Cytokine determinants of viral tropism. Nat Rev Immunol2009;9: 645–655.
  • Katze MG, He Y, Gale M Jr.Viruses and interferon: a fight for supremacy. Nat Rev Immunol2002;2: 675–687.
  • Dankar SK, Miranda E, Forbes NE et al.Influenza A/Hong Kong/156/1997(H5N1) virus NS1 gene mutations F103L and M106I both increase IFN antagonism, virulence and cytoplasmic localization but differ in binding to RIG-I and CPSF30. Virol J2013;10: 243.
  • Tumpey TM, Szretter KJ, van Hoeven N et al.The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol2007;81: 10818–10821.
  • Yang Y, Zhang L, Geng H et al.The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell2013;4: 951–961.
  • Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P.Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J Immunol2004;173: 1535–1548.
  • Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T.Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Molecular Cell1998;1: 507–518.
  • Onoguchi K, Yoneyama M, Takemura A et al.Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem2007;282: 7576–7581.
  • Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I.IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol2007;179: 3434–3442.
  • Thomson SJ, Goh FG, Banks H et al.The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc Natl Acad Sci USA2009;106: 11564–11569.
  • Genin P, Vaccaro A, Civas A.The role of differential expression of human interferon—a genes in antiviral immunity. Cytokine Growth Factor Rev2009;20: 283–295.
  • Honda K, Takaoka A, Taniguchi T.Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity2006;25: 349–360.
  • Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS.Transcriptional regulation of IFN-lambda genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kappaB complex. J Biol Chem2014;289: 5310–5319.
  • Griffiths SJ, Koegl M, Boutell C et al.A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog2013;9: e1003514.
  • Duggal P, Thio CL, Wojcik GL et al.Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med2013;158: 235–245.
  • Bibert S, Roger T, Calandra T et al.IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med2013;210: 1109–1116.
  • Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee S, Kundu TK.A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-kappaB-mediated gene transcription. PLoS ONE2013;8: e75495.
  • Fischer J, Bohm S, Scholz M et al.Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology2012;55: 1700–1710.
  • Smith KR, Suppiah V, O’Connor K et al.Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med2011;3: 57.
  • de Castellarnau M, Aparicio E, Parera M et al.Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS ONE2012;7: e31016.
  • McFarland AP, Horner SM, Jarret A et al.The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol2014;15: 72–79.
  • Honda M, Shirasaki T, Shimakami T et al.Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes. Hepatology2014;59: 828–838.
  • Dill MT, Duong FH, Vogt JE et al.Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology2011;140: 1021–1031.
  • Rallon NI, Soriano V, Naggie S et al.Impact of IL28B gene polymorphisms on interferon-lambda3 plasma levels during pegylated interferon-alpha/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother2012;67: 1246–1249.
  • Tanaka Y, Nishida N, Sugiyama M et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009;41: 1105–1109.
  • Shi X, Pan Y, Wang M et al.IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS ONE2012;7: e37054.
  • Haralambieva IH, Ovsyannikova IG, Kennedy RB et al.Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine2011;29: 7883–7895.
  • Jimenez-Sousa MA, Berenguer J, Fernandez-Rodriguez A et al.IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat2014;21: 189–197.
  • Suppiah V, Moldovan M, Ahlenstiel G et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet2009;41: 1100–1104.
  • Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R.Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem2009;284: 20869–20875.
  • Reboul J, Gardiner K, Monneron D, Uze G, Lutfalla G.Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res1999;9: 242–250.
  • Josephson K, Logsdon NJ, Walter MR.Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity2001;15: 35–46.
  • Magracheva E, Pletnev S, Kotenko S, Li W, Wlodawer A, Zdanov A.Purification, crystallization and preliminary crystallographic studies of the complex of interferon-lambda1 with its receptor. Acta Crystallogr Sect F Struct Biol Cryst Commun2010;66: 61–63.
  • Yoon SI, Jones BC, Logsdon NJ et al.Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure2010;18: 638–648.
  • Witte K, Gruetz G, Volk HD et al.Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun2009 10: 702–714.
  • Brand S, Beigel F, Olszak T et al.IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol2005;289: G960–G968.
  • Doyle SE, Schreckhise H, Khuu-Duong K et al.Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology2006;44: 896–906.
  • Maher SG, Sheikh F, Scarzello AJ et al.IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther2008;7: 1109–1115.
  • Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC.Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J2003;370: 391–396.
  • Yang L, Luo Y, Wei J, He S.Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med2010;25: 807–812.
  • Liu BS, Janssen HL, Boonstra A.IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood2011;117: 2385–2395.
  • Duong FH, Trincucci G, Boldanova T et al.IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med2014;211: 857–868.
  • Kohli A, Zhang X, Yang J et al.Distinct and overlapping genomic profiles and antiviral effects of interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat2012;19: 843–853.
  • Robek MD, Boyd BS, Chisari FV.Lambda interferon inhibits hepatitis B and C virus replication. J Virol2005;79: 3851–3854.
  • Wang Y, Li J, Wang X et al.Hepatitis C virus impairs TLR3 signaling and inhibits IFN-lambda 1 expression in human hepatoma cell line. Innate Immun2014;20: 3–11.
  • Sedger LM.microRNA control of interferons and interferon induced anti-viral activity. Mol Immunol2013;56: 781–793.
  • Jimenez-Sousa MA, Berenguer J, Rallon N et al.IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. J Viral Hepat2013;20: 358–366.
  • Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F et al.A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet2010;42: 985–990.
  • Li Y, Cheng H, Zuo XB et al.Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. J Med Genet2013;50: 812–818.
  • Malhotra S, Morcillo-Suarez C, Brassat D et al.IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. J Neuroimmunol2011;239: 101–104.
  • Lopez de Lapuente A, Alloza I, Goertsches R et al.Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. J Neuroimmunol2012;245: 98–101.
  • Vandenbroeck K, Alvarez J, Swaminathan B et al.A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes Immun2012;13: 21–28.
  • Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G.The stability of the ternary interferon–receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem2008;283: 32925–32936.
  • Kelly C, Klenerman P, Barnes E.Interferon lambdas: the next cytokine storm. Gut2011;60: 1284–1293.
  • Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC.Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem2004;279: 32269–32274.
  • Steed A, Buch T, Waisman A, Virgin HW 4th.Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol2007;81: 6134–6140.
  • Gough DJ, Levy DE, Johnstone RW, Clarke CJ.IFNgamma signaling—does it mean JAK–STAT? Cytokine Growth Factor Rev2008;19: 383–394.
  • Kearney S, Delgado C, Lenz LL.Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections. Immunol Res2013;55: 187–200.
  • Malakhova OA, Kim KI, Luo JK et al.UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J2006;25: 2358–2367.
  • Mordstein M, Kochs G, Dumoutier L et al.Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog2008;4: e1000151.
  • Mordstein M, Neugebauer E, Ditt V et al.Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol2010;84: 5670–5677.
  • Marcello T, Grakoui A, Barba-Spaeth G et al.Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology2006;131: 1887–1898.
  • Mahlakoiv T, Ritz D, Mordstein M et al.Combined action of type I and type III interferon restricts initial replication of SARS-Coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol2012;93: 2601–2605.
  • Yoshimura A, Naka T, Kubo M.SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol2007;7: 454–465.
  • Ghosh S, Hayden MS.New regulators of NF-kappaB in inflammation. Nat Rev Immunol2008;8: 837–848.
  • Thomas E, Gonzalez VD, Li Q et al.HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology2012;142: 978–988.
  • Jilg N, Lin W, Hong J et al.Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and IL28B are altered by infection with hepatitis C virus. Hepatology2014;59: 1250–1261.
  • Younossi ZM, Birerdinc A, Estep M, Stepanova M, Afendy A, Baranova A.The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med2012;10: 25.
  • Sarasin-Filipowicz M, Wang X, Yan M et al.Alpha interferon induces long-lasting refractoriness of JAK–STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol2009;29: 4841–4851.
  • Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B et al.USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE2011;6: e22200.
  • Dill MT, Makowska Z, Duong FH et al.Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology2012;143: 777–786.
  • Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al.Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA2008;105: 7034–7039.
  • Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W.Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med2009;15: 31–33.
  • Honda M, Sakai A, Yamashita T et al.Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology2010;139: 499–509.
  • Abe H, Hayes CN, Ochi H et al.Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol2011;83: 1597–1607.
  • Chen L, Borozan I, Feld J et al.Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology2005;128: 1437–1444.
  • Feld JJ, Nanda S, Huang Y et al.Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology2007;46: 1548–1563.
  • Lau DT, Negash A, Chen J et al.Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology2013;144: 402–413.
  • Manry J, Laval G, Patin E et al.Evolutionary genetic dissection of human interferons. J Exp Med2011;208: 2747–2759.
  • Ge D, Fellay J, Thompson AJ et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009;461: 399–401.
  • Uehata T, Akira S.mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. Biochim Biophys Acta2013;1829: 708–713.
  • Urban TJ, Thompson AJ, Bradrick SS et al.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology2010;52: 1888–1896.
  • Maekawa S, Sakamoto M, Miura M et al.Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to peginterferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology2012;56: 1611–1621.
  • Gullberg E, Cao S, Berg OG et al.Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog2011;7: e1002158.
  • Morishima C, Polyak SJ, Ray R et al.Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis2006;193: 931–940.
  • Sarrazin C, Mihm U, Herrmann E et al.Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. J Infect Dis2005;192: 1710–1719.
  • Rousseau CM, Daniels MG, Carlson JM et al.HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol2008;82: 6434–6446.
  • Rentenaar RJ, Gamadia LE, van DerHoek N et al.Development of virus-specific CD4+ T cells during primary cytomegalovirus infection. J Clin Invest2000;105: 541–548.
  • Duarte-Rojo A, Veldt BJ, Goldstein DD et al.The course of posttransplant hepatitis c infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation2012;94: 197–203.
  • Cisneros E, Banos I, Citores M et al.Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation2012;94: 275–280.
  • Russell CD, Griffiths SJ, Haas J.Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol2014;33: 60–63.
  • Trevino A, Lopez M, Vispo E et al.Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis2012;55: e1–e4.
  • Kamihira S, Usui T, Ichikawa T et al.Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol J2012;9: 40.
  • Bravo D, Solano C, Gimenez E et al.Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol2013;86: 838–844.
  • Mosser DM, Edwards JP.Exploring the full spectrum of macrophage activation. Nat Rev Immunol2008;8: 958–969.
  • Gunthner R, Anders HJ.Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm2013;2013: 731023.
  • Novak ML, Koh TJ.Macrophage phenotypes during tissue repair. J Leukoc Biol2013;93: 875–881.
  • van Dyken SJ, Locksley RM.Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol2013;31: 317–343.
  • Kohu K, Ohmori H, Wong WF et al.The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3. J Immunol2009;183: 7817–7824.
  • Mennechet FJ, Uze G.Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood2006;107: 4417–4423.
  • Croft M.The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol2009;9: 271–285.
  • Steinman RM, Hawiger D, Nussenzweig MC.Tolerogenic dendritic cells. Annu Rev Immunol2003;21: 685–711.
  • Trinchieri G, Sher A.Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol2007;7: 179–190.
  • Glimcher LH, Murphy KM.Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev2000;14: 1693–1711.
  • Kaplan MH, Schindler U, Smiley ST, Grusby MJ.Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity1996;4: 313–319.
  • Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE.Stat6 is necessary and sufficient for IL-4’s role in Th2 differentiation and cell expansion. J Immunol2001;166: 7276–7281.
  • Zhu J, Min B, Hu-Li J et al.Conditional deletion of Gata3 shows its essential function in TH1–TH2 responses. Nat Immunol2004;5: 1157–1165.
  • Lohoff M, Mak TW.Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol2005;5: 125–135.
  • Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G.IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood2009;113: 5829–5838.
  • Jordan WJ, Eskdale J, Srinivas S et al.Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun2007;8: 254–261.
  • Koltsida O, Hausding M, Stavropoulos A et al.IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med2011;3: 348–361.
  • Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G.Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology2008;125: 492–502.
  • Gallagher G, Megjugorac NJ, Yu RY et al.The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res2010;30: 603–615.
  • Bullens DM, Decraene A, Dilissen E et al.Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy2008;38: 1459–1467.
  • Edwards MR, Johnston SL.Deficient interferon in virus-induced asthma exacerbations. Clin Exp Allergy2008;38: 1416–1418.
  • Baraldo S, Contoli M, Bazzan E et al.Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol2012;130: 1307–1314.
  • Contoli M, Message SD, Laza-Stanca V et al.Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med2006;12: 1023–1026.
  • Russell CD, Griffiths SJ, Haas J.Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol2014;33: 60–63.
  • Chi B, Dickensheets HL, Spann KM et al.Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol2006;80: 5032–5040.
  • Hummelshoj L, Ryder LP, Poulsen LK.The role of the interleukin-10 subfamily members in immunoglobulin production by human B cells. Scand J Immunol2006;64: 40–47.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.